Literature DB >> 2764614

Neoadjuvant therapy of squamous cell carcinoma of the esophagus: role of resection and benefit in partial responders.

V L Lackey1, M T Reagan, R A Smith, W J Anderson.   

Abstract

Twenty-eight patients were treated between 1981 and 1987 with a combination of radiation therapy and two courses of 5-fluorouracil and cisplatin followed by esophageal resection. Sixteen patients (57%) underwent resection. Operative mortality was 6% (1 of 16), and the 15 operative survivors have been followed for more than 23 months. Complete pathological response was achieved in 8 of the 15 patients, and 10 patients (66%) are alive with no evidence of disease; 4 patients (27%) have survived with no evidence of disease for more than 5 years. Four partial responders are alive, and 3 are alive with no evidence of disease for more than 5 years. An aggressive approach with a low mortality has demonstrated survival benefit to complete responders and, contrary to findings of previous reports, has established a role for surgical resection and survival benefit in patients with partial response, with 3 of 7 (47%) patients surviving more than 5 years.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2764614     DOI: 10.1016/0003-4975(89)90073-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Usefulness of preoperative low dose cisplatin treatment for advanced esophageal cancer.

Authors:  M Imamura; Y Shimada; Y Kanda; M Fukumoto; K Yanagibashi; T Miyahara; T Tobe
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

Review 2.  Multimodal treatment for squamous cell esophageal cancer.

Authors:  U Fink; H J Stein; H Wilke; J D Roder; J R Siewert
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

3.  Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.

Authors:  M K Ferguson; L B Reeder; P C Hoffman; D J Haraf; L C Drinkard; E E Vokes
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

4.  The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.

Authors:  F G Duhaylongsod; M R Gottfried; J D Iglehart; A L Vaughn; W G Wolfe
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.